Aerovate Therapeutics, Inc.'s latest layoff filing, on July 1, 2024, states a cut of about 78% of its workforce. As of November 14, 2026, it has reported 2 exit or restructuring plans to the SEC on Form 8-K under Item 2.05. No WARN notice under its name is on file in the states covered here (Form 8-K, July 1, 2024).
10 companies announced layoffs this week, 1 had other signals.
Companies cutting jobs this week. Before you unlock: the company, the number of employees and what is inside. After: every way we found to reach the company. No individual is named in a layoff.
| UPWORK, INC | announced layoffs | |
| PVH CORP. /DE/ | announced layoffs | |
| Battelle | filed a layoff notice for 15 employees | |
| TidalHealth Primary Care | filed a layoff notice for 5 employees | |
| Phunware, Inc. | announced layoffs |
Is this your company?
Owed money by them or selling to them? See the free Snapshot of Aerovate Therapeutics, Inc.
Free to see. No signup.
People from Aerovate Therapeutics, Inc. who say they are open to work
Only people who added themselves are listed here. Nobody is named because of a company announcement or a news story, and we have not checked what anyone says about themselves.
Loading the list…
Affected by the Aerovate Therapeutics, Inc. layoff? Add yourself to the open-to-work list, free
Your entry
Aerovate Therapeutics, Inc. reported 2 exit or restructuring plans on Form 8-K under Item 2.05. Each fact below is the filing's own sentence, quoted and linked. No WARN notice under this company's name is on file in the states covered here.
Did Aerovate Therapeutics have layoffs in 2024? What its filings say
Aerovate Therapeutics, Inc. (CIK 1798749) reported 2 exit or restructuring plans to the SEC on Form 8-K under Item 2.05. The sentences below are quoted from the filings as written.
Form 8-K/A filed 2024-07-01
Share of workforce
The Company initiated the first wave of its Workforce Reduction Plan by notifying 39 individuals, or 78% of the Company's workforce, of their termination.
Expected charges
In connection with the Workforce Reduction Plan, the Company estimates that it will be incurring costs (in consideration of releases) of approximately $5.6 million, which are primarily one-time severance benefits.
Timing
These costs are expected to be incurred in the third and fourth quarter of 2024.
Form 8-K filed 2024-06-28
Share of workforce
The Company initiated the first wave of its Workforce Reduction Plan by notifying 39 individuals, or 78% of the Company's workforce, of their termination.
Expected charges
In connection with the Workforce Reduction Plan, the Company estimates that it will be incurring costs (in consideration of releases) of approximately $5.6 million, which are primarily one-time severance benefits.
Timing
These costs are expected to be incurred in the third and fourth quarter of 2024.
Also on the record for Aerovate Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Stake report, Schedule 13G, by Franklin Templeton, Inc. | 6% of the class | 5%+ stakes | Source |
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Bellevue Group AG | 5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 8.3% of the class | 5%+ stakes | Source |
| July 17, 2026 | Stake report, Schedule 13G, by Paradigm BioCapital Advisors LP | 5.1% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP Ltd. | 10.6% of the class | 5%+ stakes | Source |
| June 26, 2026 | Leadership change: Mark Eisner appointed | — | Leadership changes | Source |
| June 9, 2026 | Stake report, Schedule 13D/A, by Fairmount Funds Management LLC | 19.99% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 6.3% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.7% of the class | 5%+ stakes | Source |
| April 22, 2026 | Leadership change: Andrew King appointed, President | — | Leadership changes | Source |
| March 5, 2026 | Stake report, Schedule 13D/A, by Sofinnova Venture Partners X, L.P. ("SVP X") | 0.3% of the class | 5%+ stakes | Source |
Keep reading
More on Aerovate Therapeutics, Inc. and the records around it.
Aerovate Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- Sofinnova Venture Partners X, L.P. ("SVP X") also filed stake reports on 1 other company: Vera Therapeutics, Inc. (Mar 2026)
- Bellevue Group AG also filed stake reports on 6 other companies: Yarrow Bioscience, Inc. (Oct 2026), Celldex Therapeutics, Inc. (May 2026), Viridian Therapeutics, Inc. (May 2026)
- Fairmount Funds Management LLC also filed stake reports on 14 other companies: Mentari Therapeutics, Inc. (Nov 2026), Alaunos Therapeutics, Inc. (Oct 2026), SPYRE THERAPEUTICS, INC. (Oct 2026)
Watch Aerovate Therapeutics, Inc.
Get an email when Aerovate Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Aerovate Therapeutics, Inc.?
Want the whole picture on Aerovate Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aerovate Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aerovate Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 25 records.
Tools for this story
Each opens in a new tab, filled in for Aerovate Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Public companies must also report to the SEC, on Form 8-K under Item 2.05, when they commit to an exit or restructuring plan that will cost them material charges, which is how most large layoffs and closures by listed companies are disclosed. Those filings are national, so they cover companies in every state. Each sentence shown from one is quoted exactly and linked to the filing; where a filing does not state a figure, none is shown.
Where this comes from
Employers covered by the federal WARN Act, and by the stricter laws some states add, must give written notice before a mass layoff or a site closure. The state labor department publishes those notices. Every row here is one of them, taken from that state's own published file and linked to it, so each figure can be checked at the source.
A notice states the employer, the location, the number of employees affected, and when the layoff or closure takes effect. It does not state a reason, and neither does this page. Where a company also appears in SEC filings under the same name and in the same state, its recorded fundraising is shown alongside, as a matter of record rather than as an explanation. New Jersey and Pennsylvania list a notice under the month it was posted or received, not the day, so their notices show a month. Tennessee gives the county rather than the city.
Who owns Jade Biosciences, Inc.? Owners, funding and legal record
Cite this page
https://mentionfox.com/layoffs/aerovate-therapeutics